These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 665711)

  • 1. 1-desamino-8-D-arginine vasopressin (DDAVP) concentration test.
    Radó JP
    Am J Med Sci; 1978; 275(1):43-52. PubMed ID: 665711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desamino arginine vasopressin (DDAVP) as a diagnostic agent.
    Somerfield SD; Hocken AG
    N Z Med J; 1977 Nov; 86(600):472-3. PubMed ID: 343010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man.
    Radó JP; Marosi J; Szende L; Borbély L; Takó J; Fischer J
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):199-209. PubMed ID: 950263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs.
    Radó JP; Marosi J; Fischer J
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 1):518-24. PubMed ID: 789414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of DDAVP in cranial diabetes insipidus as compared to other antidiuretic drugs.
    Coculescu M; Antipa C; Cucu C
    Endocrinologie; 1977; 15(4):275-81. PubMed ID: 563614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A standardized desmopressin test of renal concentrating ability.
    Nadvorníková H; Schück O; Cort JH
    Clin Nephrol; 1980 Sep; 14(3):142-7. PubMed ID: 7418281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDAVP in the treatment of central diabetes insipidus.
    Robinson AG
    N Engl J Med; 1976 Mar; 294(10):507-11. PubMed ID: 1250255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the antidiuretic effects of Adiuretin-SD (DDAVP) and Pitressin Tannate in diabetes insipidus.
    Czakó L; Julesz J; László FA
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):10-3. PubMed ID: 631964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary concentration capacity in neonatal hydronephrosis].
    Orejas Rodríguez-Arango G; García Vicente S; Rey Galán C; Ramos Aparicio A; Santos Rodríguez F; Málaga Guerrero S
    An Esp Pediatr; 1993 Jan; 38(1):10-2. PubMed ID: 8439070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A short-term test using DDAVP for determination of the renal concentration capacity (author's transl)].
    Némethová V; Lichardus B; Lehotská V
    Monatsschr Kinderheilkd (1902); 1977 Mar; 125(3):165-7. PubMed ID: 859507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of vasopressin analogue DDAVP in patients with postoperative diabetes insipidus (author's transl)].
    Kubota T; Kashiwara K; Ito H; Tani K; Yamamoto S
    No To Shinkei; 1981 Jun; 33(3):617-23. PubMed ID: 7259900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lengthening of the duration of action of DDAVP by "ineffective" doses of clofibrate in patients with pituitary diabetes insipidus.
    Radó JP; Marosi J
    Endokrinologie; 1976 Jun; 67(2):220-9. PubMed ID: 954691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II.
    Radó JP; Simatupang T; Boer P; Dorhout Mees EJ
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):22-6. PubMed ID: 631967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term treatment of central diabetes insipidus with oral DDAVP].
    Carraro A; Fano M; Cuttica M; Bernareggi V; Giusti M; Giordano G
    Minerva Endocrinol; 1992; 17(4):189-93. PubMed ID: 1308923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DDAVP in the treatment of acute neurosurgical diabetes insipidus].
    Zancaner F; Griner A; Galante E
    Minerva Med; 1984 Apr; 75(18):1063-7. PubMed ID: 6728257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experiences with intranasal and parenteral use of 1-desamino-8-D-arginine vasopressin (DDAVP). Use in the diagnosis of hypophyseal function].
    Tuschy U; Szeszat S; Meinhold J
    Z Gesamte Inn Med; 1983 Sep; 38(17):475-7. PubMed ID: 6636917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the dose of 1-deamino-8-d-arginine vasopressin (ddavp) and the antidiuretic response in man.
    Radó JP; Marosi J; Fischer J; Takó J; Kiss N
    Endokrinologie; 1975 Nov; 66(2):184-95. PubMed ID: 1236681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DDAVP in the treatment of hypophyseal diabetes, nocturnal enuresis and in rapid determination of the concentrating function of the kidney].
    Likhardus V; Nemetova V; Legotska V
    Sov Med; 1976 Oct; (10):106-9. PubMed ID: 1023360
    [No Abstract]   [Full Text] [Related]  

  • 19. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiuretic action of oxytocin is associated with increased urinary excretion of aquaporin-2.
    Joo KW; Jeon US; Kim GH; Park J; Oh YK; Kim YS; Ahn C; Kim S; Kim SY; Lee JS; Han JS
    Nephrol Dial Transplant; 2004 Oct; 19(10):2480-6. PubMed ID: 15280526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.